CYP19A1 and breast cancer: The Committee agreed that this was not an issue of age discrimination because other factors can also affect whether people are fit enough to receive chemotherapy, such as comorbidities.’ TA257 Breast cancer (metastatic hormone receptor) – lapatinib and trastuzumab (with aromatase inhibitor)